We are thrilled to announce that Math Biology, an innovative start-up revolutionizing health technology, has successfully raised $1,500,000 in its latest funding round. This significant investment will be pivotal in advancing our mission to provide non-invasive health screening solutions for the Clinical and Wellness & Sport sectors. Our cutting-edge technology allows for a comprehensive examination of organs and cerebral districts, significantly enhancing the standard clinical tests. The funds will primarily be utilized to further develop our flagship product, the Deep Metabolism Assessment (DMA), which leverages a wealth of data鈥攐ver 20,000 sets鈥攖o advance early disease diagnosis and personalized care interventions. By identifying patterns linked to altered metabolic reactions (dysmetabolism), our approach not only promises to predict illness but also supports timely treatments and continuous monitoring. Utilizing innovative biosensors akin to ECG technology, we capture subtle electrical signals across various body points, which are then analyzed through sophisticated artificial intelligence algorithms. This uniquely positions us to assess the health status of specific organs, the Central Nervous System (CNS), and glands with unprecedented accuracy. We are immensely grateful to our investors for their belief in our vision and are excited to embark on this new chapter, paving the way for accessible, non-invasive health technology that enhances quality of life. Stay updated on our journey by visiting us at www.MathBiology.tech.
Revolutionizing Healthcare: Math Biology Secures $1.5 Million in Funding for Breakthrough Health Technology
Recently funded 路 $1.5MHealth Technology
Get the full Math Biology company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Epitome Therapeutics
Epitome Therapeutics is a biotechnology company advancing precision epigenome editing for programmable gene expression. Founded in 2025 as a spin-off from EMBL, Epitome is developing CADENCE, a next-generation platform designed to enable the precise and durable calibration of gene dosage without altering the underlying DNA sequence. The company aims to establish new therapeutic approaches for diseases driven by dysregulated gene activity, including rare and metabolic disorders.
$2.3M Pre-seed
today
Xentra
From cyber security, through to safeguarding and compliance, we provide digital security solutions perfectly designed to suit any requirement. Our team of experts will help you assess, select and implement the right solutions for your organisation; setting you up for success and helping you deliver against key objectives. We pride ourselves on understanding the digital security landscape, thoroughly evaluating available technologies and building long-term partnerships with our customers. We don鈥檛 believe in quick fixes. Whether you require a point solution to tackle a single requirement, or would benefit from a complete managed service, our solutions are built to stand the test of time. Since 2020, we鈥檝e been helping organisations such as Leeds United Football Club, Thomas鈥檚 London Day Schools, Setfords, JT Atkinson and Northern Estate Agencies Group, manage and optimise their overall digital security. Along the way, we have set the standard for what a customer-first approach to digital security looks like, and how to measure success.
